News
2021.08.17
Continues making investments in R&D
Paradigm shift in the pharmaceutical industry by large-scale technology exports in 2015
Global clinical trials for treatment of rare diseases and cancers
The first anniversary of the death of Lim Sung-ki, Former Chairman, CEO and the founder of Hanmi Pharmaceutical Group commemorated on July 30 and August 2. ⓒHanmi Pharmaceutical
"A strong fighting spirit has been engraved in the DNA of Hanmi Pharmaceutical Group to face never-ending challenges in developing global innovative new drugs and R&D" (A tribute by Song Young-sook, Chairwoman of Hanmi Pharmaceutical Group)
It has already been a year since Lim Sung-ki, Former Chairman, CEO and the founder of Hanmi Pharmaceutical Group passed away. In accordance with the spirit of the founder who aspired to make Hanmi Pharmaceutical a pharmaceutical powerhouse, Hanmi Pharmaceutical continues to make the highest level of R&D investment in the industry.
◆ Paradigm shift in the pharmaceutical industry by technology exports in 2015
Every year, Hanmi Pharmaceutical makes investments in R&D, more than 20% of its sales, The company has the highest levels of R&D investments in the industry. This steady R&D investment paid off in 2015.
In 2015, Hanmi Pharmaceutical signed technology export contracts for a total of six candidate substances, including new drugs for diabetes, obesity/diabetes and lung cancer. At that time, the contracts signed by Hanmi Pharmaceutical alone amounted to about ₩8 trillion.
In the year after the company's greatest achievement in 2015, Former Chairman Lee gave all employees of Hanmi Pharmaceutical Group his own 900,000 shares of Hanmi Science, a holding company by way of a gift.
Hanmi Pharmaceutical's achievements played a significant role in an industrial paradigm shift as a whole, not individual companies. Starting in 2015, 'global advancement' has become a hot topic in the pharmaceutical industry.
A number of global pharmaceutical companies have begun to take an interest in Korea, which was a barren land for new drug development. Technology export contracts worth trillions have been made one after another.
◆ Global novel drug candidates waiting in line… paying attention to new biopharma drugs
Hanmi Pharmaceutical has its focus on an innovative drug for treatment of NASH along with inflammation and fibrosis as well as for metabolic diseases, cancers and rare diseases as its main pipeline.
In particular, LAPSTriple Agonist (HM15211), a triple-acting drug of Hanmi Pharmaceutical, has recently received significant global attention as the world's most effective treatment for NASH, proving the effect of reducing liver fat content by more than 50% through clinical trials. The effect of reducing liver fat content within 12 weeks was up to 80% compared with placebo, and there was a significant decrease in liver enzyme levels.
Based on such strong clinical results, LAPSTriple Agonist is currently in the process of global Phase II clinical trials, and has received Fast Track designation from FDA to expedite drug development for NASH.
LAPSTriple Agonist (HM15211) was also designated as an orphan drug for the treatment of primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC) by the FDA in 2020. Hanmi plans to expand the indications and confirm the possibility of treatment for idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD).
As LAPSGLP/GCG Analog (Efinopegdutide), out licensed to MSD in 2020, entered Phase II clinical trials in this year, its development as a treatment for NASH is expected to accelerate further.
The company also focuses on the development of immuno-oncology drugs, new drugs for inflammation and fibrosis, new platforms, and new drugs for rare diseases.
which received the Fast Track designation by the FDA
Hanmi Pharmaceutical successfully conducted clinical trials of “poziotinib” on non-small cell lung cancer (NSCLC) patients with HER2 mutations in the second half of last year, received Fast Track designation from the FDA, and plans to file an application for FDA approval to “poziotinib” in the second half of the year.
Belvarafenib (HM95573, for treating solid tumors), out licensed to Genentech, is about to enter global clinical trials. FLT3/SYK dual Inhibitor (HM43239), which showed complete remission in patients with FLT3-mutated acute myeloid leukemia (AML), who failed conventional treatment, is about to enter clinical trials seeking dose increase and expansion.
Global Phase III clinical trials of efpeglenatide, which is being developed as a diabetes treatment, were conducted in a large-scale involving more than 4,000 patients, and demonstrated a significant reduction of major adverse cardiovascular events (MACE) and kidney disease in patients.
Hanmi Pharmaceutical Group established the LIM Foundation (Chairman Lee Gwan-sun) to pass on Lim's R&D management philosophy to future generations.
The LIM Foundation is a non-profit foundation that seeks to contribute to the development of pharmaceutical and biotech sector and human health. The Foundation, which Former Chairman Lim Sung-ki had prepared for its establishment during his lifetime, was eventually established by the bereaved family after Former Chairman’s death as a top priority.
Source: Newdaily